CAMBRIDGE, UK – 31 March 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced it has been granted approval to take its lead USP30 DUB inhibitor, MTX652, into clinical study. Mitochondria are essential for energy production and cellular health. When they […]

CAMBRIDGE, UK – 22 March 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced that Dr Paul Wallace, Chief Business Officer, will attend the sixteenth annual BIO-Europe Spring conference (28-31 March). BIO-Europe Spring is one of the most international gatherings in […]

CAMBRIDGE, UK – 7 March 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced that its VP of Translational Science, Dr Andy Pearce, will attend and present at the Babraham Research Campus Signalling Event on 9 March 2022. In his presentation, […]

CAMBRIDGE, UK – 6th March 2019 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that Dr Anker Lundemose, CEO, will present a company overview at the Cowen and Company 39th Annual Healthcare Conference, in Boston, Massachusetts. The presentation […]